Komori
Medinet (2370) · FactWorsenedLatest Earnings (2026-05-13): "Mitigated"

Increase in Cash Used in Operating Activities

First written in FY2017-Q2. 9 of 15 entries say "Worsened", first in FY2017. Latest entry: 2026-05-13.

15entries
10years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseWorsenedFY2017 – FY2018-Q2OtherFY2019-Q2 – FY2020-Q2WorsenedFY2021-Q2 – FY2022WorsenedFY2023 – FY20252017: 220172018: 120182019: 220192020: 120202021: 120212022: 220222023: 220232024: 120242025: 220252026: 12026
Same theme, other companies
Increases and decreases in cash flow from operating activities (causes not identified)A theme 79 companies write about · 57 as a headwind · 7 as a tailwind

Medinet moved to the "Worse" side of this theme in 2017, 8 years before the typical company in this theme (2025).

The whole theme swung hardest in 2017: 6 of 27 companies on the "Worse" side.

10 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 79 companies compared. The sentences above are computed from all 79.
Full recordFilings, disclosures and news, newest first
  1. 2026-05-13MitigatedEarnings

    「Cash used in operating activities amounted to ¥652 million, compared with ¥754 million used in the same period of the previous year.」

    Cash used in operating activities declined from ¥754 million in the same period of the previous year to ¥652 million.
  2. FY2025WorsenedAnnual report

    「Cash used in operating activities was ¥1,413 million, compared with ¥1,271 million used in the previous fiscal year.」

    Cash used in operating activities increased from ¥1,271 million in the previous fiscal year to ¥1,413 million.
  3. FY2025-H1WorsenedAnnual report

    「Cash used in operating activities was ¥754 million, compared with ¥573 million used in the same period of the previous year.」

    Cash used in operating activities increased from ¥573 million in the same period of the previous year to ¥754 million.
  4. FY2024-Q2WorsenedAnnual report

    「Cash used in operating activities was ¥573 million, compared with ¥563 million used in the same period of the previous year.」

    Cash used in operating activities increased from ¥563 million in the same period of the previous year to ¥573 million.
  5. FY2023WorsenedAnnual report

    「Cash used in operating activities was ¥1,263 million, compared with ¥1,161 million used in the previous fiscal year.」

    Cash used in operating activities increased from ¥1,161 million in the previous fiscal year to ¥1,263 million.
  6. FY2023-Q2Decrease in cash used in operating activitiesAnnual report

    「Cash used in operating activities was ¥563 million, compared with ¥612 million used in the same period of the previous year.」

    Cash used in operating activities decreased from ¥612 million in the same period of the previous year to ¥563 million.
  7. FY2022WorsenedAnnual report

    「Cash used in operating activities was ¥1,161 million, compared with ¥974 million used in the previous fiscal year.」

    Cash used in operating activities increased from ¥974 million in the previous fiscal year to ¥1,161 million.
  8. FY2022-Q2WorsenedAnnual report

    「Cash used in operating activities was ¥612 million, compared with ¥434 million used in the same period of the previous year.」

    Cash used in operating activities increased from ¥434 million in the same period of the previous year to ¥612 million.
  9. FY2021-Q2WorsenedAnnual report

    「Cash used in operating activities was ¥434 million, compared with ¥226 million used in the same period of the previous year.」

    Cash used in operating activities increased from ¥226 million in the same period of the previous year to ¥434 million.
  10. FY2020-Q2Decrease in cash used in operating activitiesAnnual report

    「Cash used in operating activities was ¥226 million, compared with ¥463 million used in the same period of the previous year.」

    Cash used in operating activities decreased from ¥463 million in the same period of the previous year to ¥226 million.
  11. FY2019Full-year operating cash flow outflow of ¥938 millionAnnual report

    「Cash used in operating activities was ¥938 million.」

    Cash used in operating activities was ¥938 million in the fiscal year under review. No comparative information was prepared for the previous fiscal year because the company transitioned to non-consolidated accounting.
  12. FY2019-Q2Decrease in cash used in operating activitiesAnnual report

    「Cash used in operating activities was ¥463 million.」

    Cash used in operating activities was ¥463 million, down from ¥1,781 million in the same period of the previous year.
  13. FY2018-Q2WorsenedAnnual report

    「Cash used in operating activities was ¥1,781 million, compared with ¥851 million used in the same period of the previous year.」

    Cash used in operating activities increased from ¥851 million in the same period of the previous year to ¥1,781 million.
  14. FY2017WorsenedAnnual report

    「Cash used in operating activities was ¥1,333.145 million, compared with ¥1,088.096 million used in the previous fiscal year.」

    Cash used in operating activities increased from ¥1,088.096 million in the previous fiscal year to ¥1,333.145 million.
  15. FY2017-Q2First statedAnnual report

    「Cash used in operating activities was ¥851 million, compared with ¥410 million used in the same period of the previous year.」

    Cash used in operating activities increased from ¥410,973 thousand in the same period of the previous year to ¥851,618 thousand.
Moved together

"Continued Operating and Ordinary Losses" moved the same way as this thread, in the same document, in 8 of its 15 moves.

875553★123456
  1. ★This thread
  2. 1Continued Operating and Ordinary Losses8×
  3. 2Accumulated Losses and Seven Consecutive Years of Net Losses7×
  4. 3Business Structure Centered on Comprehensive Immune Cell Therapy Support Services5×
  5. 4Revenue Growth Including Income from New Businesses5×
  6. 5Change in the Use of Proceeds Following the Discontinuation of Argos's Development Program5×
  7. 6Decline in Patient Numbers at Contract Medical Institutions3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Medinet yet. It last moved in the Earnings of 2026-05-13: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.